Guideline Concordant Therapy Prolongs Survival in HER2-Positive Breast Cancer Patients: Results from a Large Population-Based Cohort of a Cancer Registry
In: BioMed Research International, Jg. 2014 (2014), S. 1-10
Online
unknown
Zugriff:
Even though randomized controlled clinical trials demonstrated improved survival by adjuvant trastuzumab treatment of HER2-positive breast cancer patients, data on its effect in clinical routine are scarce. This study evaluated the use and efficacy of trastuzumab in routine treatment of HER2-positive breast cancer patients. Data from the clinical cancer registry Regensburg (Germany) were analyzed. The present study investigated 6,991 female patients with primary invasive breast cancer. In premenopausal HER2-positive patients a considerable increase of trastuzumab therapy was observed from 58.1% in 2006 to 90.9% in 2011, whereas in postmenopausal patients trastuzumab was rather used on a constant rate of 49.1%. Best overall survival (OS) was found in HER2/steroid hormone receptor-positive patients receiving guideline concordant treatment with trastuzumab plus chemotherapy (CHT) plus antihormone therapy (AHT) with a 7-year OS rate of 96% compared to the non-trastuzumab group with a 7-year OS rate of 92%. In multivariable analysis, HER2-positive patients treated with CHT or AHT who did not get trastuzumab, had a worse 7-year OS (65%,P=0.006versus 79%,P=0.017) than the control groups. This population-based study demonstrated that guideline concordant use of adjuvant trastuzumab improves OS for HER2-positive breast cancer patients treated in routine clinical care.
Titel: |
Guideline Concordant Therapy Prolongs Survival in HER2-Positive Breast Cancer Patients: Results from a Large Population-Based Cohort of a Cancer Registry
|
---|---|
Autor/in / Beteiligte Person: | Ortmann, O ; Zeman, Florian ; Klinkhammer-Schalke, Monika ; Inwald, E. C. ; Koller, Michael ; Gerstenhauer, M. ; Hofstädter, Ferdinand |
Link: | |
Zeitschrift: | BioMed Research International, Jg. 2014 (2014), S. 1-10 |
Veröffentlichung: | Hindawi Limited, 2014 |
Medientyp: | unknown |
ISSN: | 2314-6141 (print) ; 2314-6133 (print) |
DOI: | 10.1155/2014/137304 |
Schlagwort: |
|
Sonstiges: |
|